Jaimy Lee

Plus, news about Vigonvi­ta Life Sci­ences and Lutris Phar­ma: For MASH de­vel­op­ers, a race for cash: Akero Ther­a­peu­tics aims to raise … Sign up to

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

The FDA re­ject­ed Ap­plied Ther­a­peu­tics’ ex­per­i­men­tal treat­ment for a rare dis­ease called clas­sic galac­tosemia, cit­ing de­fi­cien­cies with the ap­pli­ca­tion. The com­pa­ny, while “dis­ap­point­ed with the

Plus, news about Telios Phar­ma and Celldex Ther­a­peu­tics: An­oth­er day, an­oth­er pub­lic of­fer­ing: Apogee Ther­a­peu­tics is aim­ing to raise $350 mil­lion in a stock sale

Plus, news about Tar­sus Phar­ma­ceu­ti­cals, Hu­ma­cyte, Stem­cell Tech­nolo­gies and SQZ Biotech­nolo­gies: Achieve Life Sci­ences rais­es $124M, de­tails plans for NDA: The com­pa­ny plans to sub­mit

Plus, news about Xen­cor, Ot­su­ka, Type­writer Ther­a­peu­tics, Cas­sa­va Sci­ences, En­ver­ic Bio­sciences, Viking Ther­a­peu­tics and Janux Ther­a­peu­tics: Next up in the PIPE bo­nan­za: RNA com­pa­ny Avid­i­ty

Mile­stone Phar­ma­ceu­ti­cals de­tails plan to re­sub­mit etri­pamil to the FDA in Q2: For its ex­per­i­men­tal treat­ment for parox­ys­mal supraven­tric­u­lar tachy­car­dia, the com­pa­ny will now “re­struc­ture

Plus, news about Telix, QSAM Bio­sciences, Nicox, and Kowa: Eli Lil­ly se­lects Foghorn can­di­date for de­vel­op­ment: Foghorn’s stock $FHTX jumped 16% on Thurs­day morn­ing af­ter